SINGAPORE, May 24, 2018 /PRNewswire/ — QT Vascular Ltd., (“QT Vascular“, and with its subsidiaries, the “Company“), announced today that it has entered into an asset purchase and option agreement (the “APOA“) with Teleflex Life Sciences Unlimited Company and Teleflex Incorporated (“Teleflex“). Under the APOA, Teleflex will acquire the non-drug coated product line […]
Author: Ken Dropiewski
Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
DUBLIN – May 24, 2018 – Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2018, which ended April 27, 2018. The company reported fourth quarter worldwide revenue of $8.144 billion, an increase of 2.9 percent as reported, or 6.5 percent on an organic basis, […]
Venus Medtech’s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market
HANGZHOU, China, May 23, 2018 /PRNewswire/ — China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation TriGUARD 3™ device and the next generation of cerebral embolic protection device in China and […]
Analytics 4 Life® Expands Its Medical Advisory Board with Global Experts in Cardiology
RESEARCH TRIANGLE PARK, N.C. & TORONTO–(BUSINESS WIRE)–Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced that it has expanded its Medical Advisory Board with the addition of two global experts in cardiology and digital health. Junbo […]
Avinger Receives FDA Clearance of Next Generation Pantheris Device
REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided […]
Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors
Malmö, May 23, 2018 Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors Acarix, developer of the CADScor®System for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of a highly experienced marketing expert, Johanne Louise Brændgaard, as a member of the board of […]
Acarix AB recruits Per Persson as Chief Commercial Officer
Malmö, May 23, 2018 Acarix AB recruits Per Persson as Chief Commercial Officer Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer to accelerate the sales execution for the CADScor®System for Coronary Artery Disease (CAD) risk assessment. He has a solid background in […]
New Medtronic Data Show Significant Blood Pressure Lowering Effect of Renal Denervation in Patients Taking Anti-Hypertensive Medication
DUBLIN and PARIS – May 23, 2018 – Medtronic plc (NYSE:MDT) today announced first-ever-data from the SPYRAL HTN-ON MED Study. Initial study results found statistically significant and clinically important blood pressure reductions in hypertensive patients prescribed anti-hypertension medications treated with the Symplicity Spyral renal denervation (RDN) system with no major adverse […]
Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy
SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom®bioresorbable scaffold (“BRS”) through two years based on data from the FANTOM II trial presented today at the […]
Berlin Cures Announces Formation of Scientific Advisory Board
ZUG, Switzerland, May 23, 2018 /PRNewswire/ — Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the clinical development of BC 007, the first drug designed to target the autoimmune cause of heart failure as […]



